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A U T H O R

Christin Pramudiati

I

just graduated with my bachelors degree in Chemical Engineering this past May. I am originally from
Indonesia, and my journey in the University of Kentucky
started in Spring, 2001. During my studies, I was a runnerup in the Physical and Engineering Sciences category of the
2006 Oswald Research and Creativity Program. Also, I was
member of Tau Beta Pi, the Engineering Honor Society, and
the American Institute of Chemical Engineers (AIChE). In
the Summer of 2005, the Nanoscale Engineering Certificate
Program (NECP) granted me a summer fellowship that has partially supported
the research reported here.
Based on my two previous research experiences and my future plan to
attend graduate school in Pharmaceutical Science, I was looking for another
research opportunity after I came back from my co-op, a year-long internship
at ISP Chemical Inc., Calvert City, KY. At that time, a new faculty member in
the department of Chemical and Material Science, Dr. J. Zach Hilt, offered me
an opportunity to take part in his joint project with Dr. Razvan Arsenescu in the
department of Internal Medicine and Gastroenterology. The project involves
developing a polymer-based (PLGA) drug delivery system for Crohn’s disease.
Through support from my mentors and the continuation of this project, I was
able to work on this research independently for one and a half years and also
obtain a strong foundation for the drug delivery–focused PhD program in Pharmaceutical Science that I am about to pursue in Fall, 2006. Moreover, from the
preliminary data obtained during this research, we are currently in the process
of filing a patent application on this novel device.
Outside of my books, I enjoy playing musical instruments, but mostly
keyboard. During the school year, I usually play keyboard at the International
Christian Fellowship (ICF). Besides being a worship leader in ICF, I am also
involved with lots of other activities that are oriented mostly to international
students. These activities include but are not limited to serving as secretary
for the International Student Council in 2002-2003 and volunteering in several
welcome weeks, activities that are put together to welcome new international
students who have just arrived on campus.
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Abstract
The purpose of this research is to develop biodegradable drug delivery systems. One of the delivery systems that we have developed is a suture-like
structure for the treatment of Crohn’s disease that
utilizes a biodegradable polymer, poly(DL-lactideco-glycolide) acid (PLGA). Crohn’s disease is an
inflammatory bowel condition. Aside from the
gut involvement, perianal complications develop
in the form of enterocutaneous fistulas. Medical
management of Crohn’s disease consists of various drugs with immunosuppressive properties.
Complicated disease manifestation requires surgical interventions in the form of bowel resection or
fistula drainage with Setons. Setons are suture-like
devices that help to drain associated abscesses and
close secondary fistulous tracts. They are often
removed prematurely to prevent entrapment as
the proximal and distal ends of the fistula heal.
In their current form, Setons are not degradable
and are not able to deliver drugs. Thus, the patients typically receive their drugs systemically.
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Her submission for publication in Kaleidoscope is original research that she
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(Internal Medicine, Gastroenterology). Christin is an exceptional student whose
meticulous methods and outstanding work ethic in the laboratory have separated
her from her peers. The specific research presented in this submission is novel
and has led to a patentable technology that promises to have application in the
controlled delivery of therapeutic agents from degradable Setons.
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The novel device, biodegradable Setons from PLGA,
that we developed promises superior treatment by
providing adequate drainage, uniform healing, and a
lower level of immunosupression. Currently, there is
a patent application filed on this novel device.
The chronic inflammation is driven by cells of
the innate and acquired immune system. Macrophages and dendritic cells (innate immune system
cells) sample luminal (gut) antigens and trigger more
specialized acquired immune responses. Targeting
these cells may break a vicious cycle that creates a
chronic state of inflammation within the gut. Drug
incorporated-biodegradable nanoparticles can mimic
inert particulate matter present in the lumen of the
gut. Thus, they may be actively sampled by dendritic
cells. Most of these cells remain within the lamina
propria of the gut or travel to the gut-associated lymph
nodes. By targeting these antigen-presenting cells, we
anticipate preventing ongoing activaction of B and T
cells (acquired immunity) and limiting the systemic
exposure to immunosuppressive drugs.
These innovative methods present a more efficient and safe drug delivery that addresses both the
chronic gut inflammation (via nanoparticles) and the
associated perianal complications (via Setons).

1. Introduction
1.1. Crohn’s Disease
Crohn’s disease is an inflammatory bowel disease
that results from a deregulated immune response to
the commensal intestinal flora. Aside from the gut
involvement, perianal complications develop in the
form of enterocutaneous fistulas. Medical management of Crohn’s disease consists of various drugs
with immunosuppressive properties. Complicated
disease manifestations require surgical interventions
in the form of bowel resection or fistula drainage
with Setons.
Figure 1.
Types of
fistulas based
on anatomical
locations

Figure 2.
Seton placed in a perianal fistula

The cumulative frequency of perianal fistulas in
patients with Crohn’s disease has been reported to
range from 14% to 38% in referral centers [1], with
17% to 28% of patients requiring surgery [2]. For
treatment of the fistulas, Tacrolimus and Infliximab
are the only drugs shown to be effective in prospective, randomized, placebo-controlled studies. The
former can be used orally and topically. In addition
to side effects associated with large dose administrations, recurrence after treatment cessation is a major
problem with both drugs. In other cases, anatomically complex and medication refractory fistulas require surgical treatment. Continuous drainage with
surgically placed Setons (see Figure 1 and 2), is an
effective, less invasive, complementary, or stand-alone
management. However, for treatment with current
Setons, the caveats are patient discomfort, associated
with long term placement of these non-resorbable
sutures, and absence of complete closure.
Therefore, creating a drug eluting, biodegradable
Seton from a PLGA system promises great benefits: (i)
the incorporated drug will be slowly and continuously
released over time while providing targeted delivery of
a lower dose, (ii) uniform healing, because the Seton
will be present in the fistulous tract even after the
distal and proximal ends (see Figure 2) have closed,
(iii) Seton entrapment is no longer an impediment,
given the biodegradable nature of these polymers.
Overall, this novel device will translate to long-lasting
therapeutic success, improved safety, and quality of
life for these patients.

1.2. Poly (DL-Lactic-Glycolic) Acid (PLGA)
There has been a great amount of research conducted
on controlled drug delivery using biodegradable
polymer systems. Compared to other biodegradable polymers, poly (D,L-lactide-co-glycolide) acid
(PLGA) systems, copolymers of poly(lactic acid)
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(PLA) and poly(glycolic acid) (PGA), have generated great interest due to their favorable properties,
including excellent biocompatibility, biodegradability,
and mechanical strength. Also, PLGA systems have
been approved by the Food and Drug Administration
(FDA) for use in drug delivery applications. PLGA
is advantageous because it biodegrades into lactic
and glycolic acids, which can then be metabolized
and eliminated from the body as carbon dioxide and
water [3].
The degradation of PLGA systems is dependent
on their physical properties (i.e., the molecular weight
and polydispersity index) and molar ratio of the individual monomer components (lactide and glycolide)
(see Figure 3) in the copolymers [3]. PLGA polymers
with a 50:50 ratio of lactic acid and glycolic acids
are hydrolyzed much faster than those containing a
higher ratio of either monomer [4] (see Figure 4).
For degradation analysis purposes, we are mainly
focusing on three different ratios of PLGA: 75:25,
65:35, and 50:50. From figure 4, it can be seen that
within the range of PLA ratios from 50% to 100%,
copolymers with higher ratios of lactide exhibit a
higher half-life, thus degrading more slowly. Therefore, as expected, PLGA with a ratio of 50:50 degrades
first, followed by 65:35 and 75:25. Degradation of
this biodegradable polymer results in a mass loss
due to the resorption or dissolution of the material,
accompanied by a reduction in molecular weight and
changes in mechanical properties such as strength
and stiffness.

C

hristin

Pramudiati

Figure 3. Chemical
Structure of PLGA
Figure 4.
Half–life of PLA and PGA
(Adapted from Reference [4])
In order to target these specific cells, the drug delivery system needs
to be designed in the nanoscale range. Particles that are less than 500
nm can cross the microfold (M) cells in the Payer’s patch or be actively
sampled by dendritic cells [9]. Therefore, based on the previous research
of Tabata [10,11,12,13] and Nakase [8] that has proven the efficient
uptake of microparticles by activated macrophages, we attempted to
tailor a controlled drug release from PLGA nanoparticles with size of
less than 1m.
PLGA nanoparticles were obtained by using an oil-in-water emulsion method. With the help of a surfactant, polyvinyl alcohol (PVA),
and stirring the emulsion at about 7900 rpm for 2 minutes, 150-250 nm
particles can be obtained by using acetone as the solvent. The size of
the nanoparticles acquired depends on several different variables, including (i) solvent choice, (ii) PLGA concentration in the solvent, (iii)
the concentration, volume, and type of surfactant, (iv) the volume ratio
of PLGA and surfactant, and (v) speed of stirring.

1.3. PLGA Nanoparticles

1.4. Polyphenols (Green Tea)

The chronic inflammation of Crohn’s disease is driven
by cells of the innate and acquired immune systems.
Macrophages and dendritic cells (innate immune
system cells) sample luminal (gut) antigen and trigger more specialized acquired immune responses.
The significant roles that macrophages and dendritic
cells play in the regulation of immune responses in
the gastrointestinal tract as antigen-presenting cells
are well known [5,6,7]. Targeting these cells may
break a vicious cycle that creates a chronic state of
inflammation within the gut [8] . Drug eluting, biodegradable nanoparticles, can mimic inert particulate
matters present in the lumen of the gut. Thus, they
may be actively sampled by dendritic cells. Most
of these cells remain within the lamina propria of
the gut or travel to the gut associated lymph nodes.
By targeting these antigen-presenting cells, we can
prevent the ongoing activation of B and T cells (acquired immunity) and limit the systemic exposure of
immunosuppressive drugs.

Green tea polyphenols are natural plant antioxidants found in tea leaves.
Much research has been done to prove that antioxidants can prevent
damage caused by free radicals to DNA and other molecules [14]. In
addition to several cancer preventive properties, these compounds may
reduce abnormal cell growth and inflammation, free the body from
cancer causing agents, and restore communication between different
cells in the body. Green tea polyphenols have also been shown to be
effective in murine models of Crohn’s disease. Polyphenols were used
as a model drug system in these experiments.

2.

Experimental Method

2.1. Preparation of the PLGA films
Three ratios of PLGA films were prepared by casting a solution of PLGA
(75:25, 65:35, or 50:50) and acetone into either aluminum or Teflon
molds. Films were dried for at least 48 hours before being peeled and
circled with a cork borer into discs with an average diameter of 8.4
mm (see Figure 5). Films with different thicknesses were obtained by
dissolving PLGA with acetone. Drug-loaded PLGA films with different
ratios (75:25, 65:35, and 50:50) were prepared in a similar manner.
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2.3. Quantification of Polyphenols’
Concentration
Prior to calibration, solutions of green tea polyphenols and PBS pH 7.4 were prepared in various concentrations: 0.0005, 0.001, 0.005, 0.010, and 0.015
mg/ml. Calibration was carried out by measuring
the absorbance of each concentration in a UV-Visible Spectrophotometer over the wavelength range
of 200 to 250 nm. Polyphenols have their strongest
absorbance at 207 nm.

2.4. Drug Release Study

Figure 5.
Preparation of PLGA film without drug incorporated. When drug
needs to be incorporated, it can be added to the system once the
polymer has dissolved.

Figure 6.
Degradation study of PLGA system using mass loss analysis

2.2. Degradation Study
A degradation study of different ratios was carried out by analyzing the
mass loss of PLGA discs at six time points: 1, 2, 3, 4, 6, and 8 weeks,
and that of different thickness of PLGA film done with 10 time points.
For error analysis, samples were prepared in triplicate. PLGA discs were
immersed in PBS (Phosphate Buffered Saline) (see Figure 6). At each
time point, discs were taken from the water bath for mass analysis, while
the PBS in the remaining samples was replaced weekly with fresh PBS.
The mass of the discs at the various time points was then compared to
their initial mass. Then, the degradation (mass at time point divided
by initial mass) was calculated.
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Discs loaded with the drug were immersed in PBS.
Samples for each ratio of PLGA (75:25, 65:35, and
50:50) were prepared in quadruplicate. For infinite
sink conditions, the PBS solution in each vial was
replaced at each time point with a fresh solution. The
absorbance of each solution was measured using a
UV-Visible Spectrophotometer at 207 nm. Then, the
absorbance data was translated to the concentration
by using the calibration curve.

2.5. PLGA Nanoparticles
Currently, the most optimized nanoparticles were
obtained by the following method: PLGA was dissolved in acetone in a centrifuge tube. If polyphenols
or another compound was to be encapsulated, it
was added after the polymer was dissolved. To this
solution, a surfactant, poly(vinyl alcohol) (PVA), was
added, and the resulting emulsion was very briefly
hand shaken before being homogenized. The emulsion was then transferred to a vacuum with additional
water used as a rinse. To remove the residual acetone,
the emulsion was stirred while under a modest
vacuum. While stirring continued, a small volume
of emulsion was removed from the flask for sizing.
All the materials used in the procedure were simply
multiplied proportionally by a factor of 1/4, 1/2, 2,
5, etc, to obtain various quantities of nanoparticles.
To remove the drug present in the surfactant, the
nanoparticles were separated using centrifugation.
The supernatant was collected and analyzed using a
UV Visible spectrophotometer (at 207 nm) to detect
the amount of polyphenols that was not encapsulated
in the nanoparticles. The pellets of nanoparticles
were combined and re-suspended in PVA solution
for release study purposes. Currently, we are still in
the process of developing a better, more efficient way
to synthesize these nanoparticles and to evaluate the
polyphenols released from this system.
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Figure 7.
Degradation of
three different
ratios of PLGA
(75:25, 65:35,
and 50:50),
N=3

3.1. Degradation Study of Different Ratios of PLGA
The degradation and drug release of PLGA varies
depending on the ratio of the PLA to PGA. The 50:50
ratio starts to degrade in 2 weeks, followed by 65:35
and 75:35. Often, we performed molecular weight
analyses instead of mass loss analyses to obtain a
more accurate degradation study. However, because
this research was conducted with a target of in vivo
drug delivery, mass loss analysis can give a good representation of the degradation and a rough estimation
of the residence time of the system in the body. To
obtain a preliminary estimate of the PLGA degradation in vitro, we carried out the study using the PLGA
discs. Wu et al. [15] reported the study of various
ratios of PLGA in the form of rods. The difference in
the geometries (between discs and rods) might give
a slightly different degradation response. However,
an in vivo study using Seton-like structures is being
planned to be carried out in the near future. Thus,
more accurate degradation of PLGA and its inflammatory response will be studied further.
The summary of the preliminary PLGA degradation study based on different ratios is presented in
Figure 7. The relatively large error bars associated
with the figures were caused by several factors,
including variance of PLGA weight percent in the
system and mass loss during solution replacement
in the experimental methods. The use of a filter and
mesh could be a way to reduce the error. Also, by
making larger PLGA films, all the discs used for the
experiment will be somewhat more homogenous,
thus, decreasing the error.

Figure 8.
Degradation
of PLGA
50:50 (I.V.:
0.58) with
three different
thicknesses by
mixing PLGA
(1, 2.5, and 5
g) and acetone
at 10% w/w,
N=3

Figure 9.
Correlation
between
concentration
of polyphenols
and absorbance,
described by
Beer’s Law

3.2. Degradation Study of Different Thicknesess
of PLGA Film
Figure 8 indicates that the degradation of PLGA also
varies depending on the thickness of the film. The
thicker PLGA film degrades a lot faster compared to
the thin one. This is due to the fact that the thicker
PLGA film tends to lower the pH of the media, causing
the film to be even easier to degrade. Due to difficulties in handling and weighing the discs, large errors
were generated with the thinnest film.
3.3. Quantification of Polyphenols Concentration
Figure 9 shows the correlation between the concentration of the polyphenols and their absorbances,
obtained from a UV-Visible spectrophotometer. The
absorbance data used was normalized at 207 nm,
where polyphenols absorbance is at its maximum.
By determining the absorbance of five different concentrations (listed in section 2.2), the constant value
of eb, 169.49, can be obtained from the linear plot,

Table 1. Summary of particle average size and the standard
deviation due to the effects of various variables
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3.5. Nanoparticles

Figure 10.
Polyphenols
release rate
from 3 different
ratios of PLGA,
N=4

Table 1 shows some values of the particle average
size along with standard deviations due to the combinations of different variables. There are many
factors that determined the size of the nanoparticles,
including: the ratio of the PLGA over the surfactant,
the amount of PLGA in the solvent, concentration
and volume of the surfactant, homogenizing time
and speed, solvent and surfactant choices, and many
more. By utilizing acetone as the solvent to dilute the
PLGA and PVA as the surfactant, the smallest size of
particles obtained during experiments were from a
ratio volume of PLGA and PVA of 3:5. At this volume
ratio, nanoparticles with the size of 150-250 nm have
been successfully synthesized.
Figure 11 shows the size of the particles, 202.15
± 41.9 nm, that were used for the release study. The
size of the particles was confirmed using a scanning
electronic microscope (Figure 12). The “strings”
observed in Figure 12 were most probably formed
due to excessive PVA that still had not been removed
from the system. PVA was kept in the system to
avoid particles aggregating. Again, we are in the
process of developing a better, more efficient method
to synthesize these nanoparticles, and the release
study of nanoparticles still also needs to be further
developed.

Figure 11.
Particle
analyzer result:
nanoparticles
size taken right
after being
homogenized

4. Conclusions
following Beer’s law. In the release study, the polyphenols incorporated in the discs were slowly released
to the PBS solution in which they were incubated. At
its time point, the absorbance of these PBS solutions
was measured using a UV-Visible Spectrophotometer.
Thus, by utilizing the attained eb value, the only unknown variable, concentration (c), can be calculated
from the measured solution absorbance (A) .

3.4. Release Study
From the release study data summary (see Figure
10), it can be seen that the release of drug is directly
related to the physical properties of the PLGA system.
Here, the ratio of the mass released at time t, Mt, over
mass released at time infinity, Minf, is plotted versus
time. The PLGA with a ratio of 50:50 released the
polyphenols first, followed by 65:35 and 75:25. Using
this release data, we can possibly tailor the release of
the drug in a similar dosage over a period of up to 4 to
5 months. The errors in the release study data were
partially generated by the inhomogeneous distribution of polyphenols in the PLGA films, which results
in a slightly different loading concentration in each
disc being studied.
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Through this research, we have successfully developed a degradable Seton from PLGA that also will
be able to release drugs locally. Because the PLGA
degradation rate in any form of device can be tailored
based on its dependency on the physical properties,
such as ratio, molecular weight, and polydispersity
index, this device promises a better therapeutic system
for Crohn’s disease patients. With these preliminary
experiments, we were able to determine the degradation rate of the PLGA at different ratios (75:25, 65:35,
and 50:50) and thicknesses using mass loss analysis.
Although there were errors associated with the mass
loss analysis, trends were observed. The release of
polyphenols in PLGA discs with different ratios was
quantified using the calibration data obtained. A
Phase I clinical study for patients with fistulizing
Crohn’s disease is in the process of being developed.
We are also attempting to optimize the nanoparticle
production and ways to analyze the release of a model
drug (e.g., polyphenols). Overall, we believe that
these drug delivery methods present a more efficient
and safe drug delivery that addresses both the chronic
gut inflammation (via nanoparticles) and the associated perianal complications (via Setons).
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